The signs of relapse after bone marrow transplant typically include unexplained fatigue, new bruising or bleeding, recurrent fevers or infections, and abnormal blood counts—particularly dropping platelets, falling hemoglobin, or rising blast cells. Relapse occurs in roughly 40–50% of patients who receive an allogeneic transplant for acute myeloid leukemia (AML), and rates vary widely depending on the original disease, its stage at transplant, and donor match quality.
Most relapses happen within the first 1–2 years after transplant, with the highest risk concentrated in the first 6 months. But here’s the critical point: modern molecular monitoring can detect relapse weeks to months before any symptoms appear. Knowing what to watch for—and what tests to push for—can make the difference between catching a recurrence when it’s still manageable and facing a full-blown relapse with limited options.
What Exactly Is a Post-Transplant Relapse?
A relapse means the original disease—usually a blood cancer like leukemia, lymphoma, or myelodysplastic syndrome (MDS)—has come back after the transplant achieved remission. The transplant’s job was twofold: destroy the diseased marrow with conditioning chemotherapy (and sometimes radiation), then replace it with healthy donor stem cells that rebuild normal blood production and mount an immune attack against residual cancer cells (graft-versus-leukemia effect).
When relapse occurs, it means residual malignant cells survived both the conditioning regimen and the donor immune system’s surveillance. These cells can re-expand slowly (molecular relapse) or explosively (hematologic relapse with rapidly rising blast counts).
8 Key Signs and Symptoms to Watch For
The clinical presentation depends on the underlying disease, but most post-transplant relapses share common patterns driven by failing bone marrow function:
| Sign or Symptom | What It Reflects | Typical Lab Finding |
|---|---|---|
| Persistent or worsening fatigue | Falling red blood cell production | Hemoglobin <10 g/dL (dropping trend) |
| Easy bruising or petechiae | Declining platelet counts | Platelets <100,000/µL |
| Unusual or prolonged bleeding | Severe thrombocytopenia | Platelets <50,000/µL |
| Recurrent or persistent fevers | Immune dysfunction / neutropenia | ANC <1,000/µL |
| Frequent infections | White blood cell suppression | WBC declining or abnormal differential |
| Bone pain (especially in AML) | Marrow expansion by blast cells | Blasts detected on peripheral smear |
| Swollen lymph nodes | Lymphoma recurrence | Elevated LDH, abnormal imaging |
| Night sweats and unexplained weight loss | “B symptoms” of active disease | Variable |
One pattern that deserves special attention: a previously stable complete blood count (CBC) that starts trending downward. A single low result might mean nothing. Three consecutive drops in platelets or hemoglobin over 2–4 weeks is a red flag that warrants immediate investigation.
When Does Relapse Typically Happen?
Timing matters. Early relapse (within 6 months of transplant) generally carries a worse prognosis than late relapse. Here’s a rough breakdown:
- 0–6 months post-transplant: Highest risk window. The donor immune system hasn’t fully established itself yet. Relapses here tend to be aggressive.
- 6–24 months: Still significant risk. Many centers intensify monitoring during this period with monthly or bimonthly labs.
- Beyond 2 years: Risk drops substantially but never reaches zero. Late relapses (3–5+ years out) do occur, particularly in chronic myeloid leukemia (CML) and some lymphomas.
How Relapse Is Detected: Tests That Catch It Early
Waiting for symptoms is essentially waiting too long. The most effective approach uses layered surveillance:
Minimal Residual Disease (MRD) Monitoring
This is the gold standard for early detection. Techniques like next-generation sequencing (NGS), multiparameter flow cytometry, and quantitative PCR can detect as few as 1 leukemic cell among 10,000–1,000,000 normal cells. Studies show that MRD positivity after transplant predicts relapse with high accuracy—one large study in AML found that MRD-positive patients had a 3-year relapse rate of 67% compared to 22% in MRD-negative patients.
Donor Chimerism Testing
Chimerism analysis measures what percentage of blood cells come from the donor versus the patient. Full donor chimerism (>95% donor cells) is the goal. Falling chimerism—especially in the T-cell fraction—is an early warning signal. A drop below 80% donor chimerism should trigger further investigation, and some centers act preemptively with donor lymphocyte infusions at this stage.
Bone Marrow Biopsy
Most transplant centers schedule bone marrow biopsies at day +30, day +100, 6 months, and 1 year post-transplant at minimum. These biopsies assess cellularity, blast percentage, and cytogenetics. A blast count ≥5% in the marrow is concerning; ≥20% confirms hematologic relapse in leukemia.
Routine Blood Work
Regular CBCs with differential remain the frontline screening tool. Patients typically get blood drawn weekly for the first few months, then biweekly, then monthly as they move further from transplant.
Risk Factors That Increase Relapse Likelihood
Not every transplant patient faces the same risk. Key factors include:
- Disease status at transplant: Patients transplanted in first complete remission (CR1) fare significantly better than those transplanted with active disease or in CR2+.
- Cytogenetics and molecular markers: Adverse-risk mutations like TP53, FLT3-ITD (with high allelic ratio), or complex karyotype carry higher relapse rates—often exceeding 50–60%.
- Donor match quality: Matched related donors generally provide the strongest graft-versus-leukemia effect. Haploidentical and mismatched unrelated donor transplants have variable outcomes depending on platform used.
- T-cell depletion: Transplants using T-cell-depleted grafts reduce graft-versus-host disease (GVHD) but also diminish the graft-versus-leukemia effect, increasing relapse risk.
- Absence of chronic GVHD: Counterintuitively, mild chronic GVHD is associated with lower relapse rates because it reflects active donor immune surveillance against residual disease.
Treatment Options After Relapse
Post-transplant relapse is treatable, but outcomes depend heavily on timing and the specific disease. Options include:
- Donor lymphocyte infusions (DLI): Infusing additional immune cells from the original donor to reignite the graft-versus-leukemia effect. Works best for CML and molecular-level relapses. Less effective for aggressive AML relapses.
- Targeted therapies: FLT3 inhibitors (gilteritinib, midostaurin), IDH inhibitors (ivosidenib, enasidenib), BCL-2 inhibitors (venetoclax), and hypomethylating agents (azacitidine, decitabine) are often used depending on the mutation profile.
- CAR T-cell therapy: Particularly effective for relapsed ALL (tisagenlecleucel) and certain lymphomas. Increasingly studied in AML.
- Second transplant: Considered in selected patients—especially those who relapsed more than 6–12 months after the first transplant and can achieve remission again before the second procedure.
- Immunomodulation: Rapid tapering of immunosuppressive medications to unleash the donor immune system against the recurring disease.
When to Contact Your Transplant Team
Don’t wait for your next scheduled appointment if you notice any of the following:
- New or worsening fatigue that isn’t explained by other causes
- Bruising that appears without trauma, or petechiae (tiny red/purple dots on the skin)
- Fevers above 100.4°F (38°C), especially if recurrent
- Night sweats that drench your clothing or sheets
- Unintentional weight loss exceeding 5% of your body weight
- New lumps or swollen lymph nodes
- Bone pain that’s new or different from baseline
Call your transplant center directly rather than going to a general emergency room whenever possible. Transplant centers have protocols specifically designed for rapid evaluation of post-transplant patients.
Frequently Asked Questions
How soon after a bone marrow transplant can relapse occur?
Relapse can technically occur at any time, but the highest risk is during the first 6–12 months. Most relapses are detected within the first 2 years. Late relapses beyond 5 years are uncommon but documented, which is why long-term follow-up remains standard practice.
Can blood tests detect relapse before I feel symptoms?
Yes—and this is exactly why regular monitoring is so critical. MRD testing and chimerism analysis can detect molecular evidence of relapse weeks to months before symptoms develop. A falling donor chimerism percentage or detectable MRD should prompt action even if you feel perfectly fine.
Is a second bone marrow transplant possible after relapse?
It is possible and is performed successfully in selected patients. The best candidates are those who relapsed more than 6–12 months after the first transplant, achieved a second remission before the repeat procedure, and have adequate organ function. Second transplants carry higher complication rates than first transplants, so the decision requires careful risk-benefit analysis with your transplant team.
Does graft-versus-host disease (GVHD) reduce relapse risk?
Mild to moderate chronic GVHD is actually associated with lower relapse rates because it signals an active donor immune system that also attacks residual cancer cells. However, severe GVHD causes significant morbidity and mortality, so the goal is never to induce GVHD—rather, if it develops mildly, it may carry a protective trade-off.
What’s the survival rate after post-transplant relapse?
This varies enormously by disease type, timing, and available treatments. For AML relapsing within 6 months of transplant, 2-year overall survival historically ranges from 10–20%. For later relapses or diseases more responsive to DLI (like CML), outcomes are substantially better. Newer therapies—particularly targeted agents and CAR T-cells—are improving these numbers, but post-transplant relapse remains one of the most challenging scenarios in hematology.
